Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated strong performance in the transcatheter aortic valve replacement (TAVR) market, with revenue growth of 10.6% year-over-year, exceeding consensus estimates. The company's transcatheter mitral and tricuspid technology (TMTT) segment saw impressive sales growth of 48.3% year-over-year, fueled by the successful adoption of products like Pascal and Evoque. Management has expressed increased confidence in achieving its 2026 sales guidance of 8-10% year-over-year growth, further reinforcing positive sentiment around the company's financial prospects.

Bears say

Edwards Lifesciences's financial outlook appears negative primarily due to underperformance in adjusted operating margin, which came in at 23.7%, falling short of the consensus estimate of 25.9% due to elevated SG&A expenses of $603 million. Furthermore, while TAVR and TMTT sales slightly exceeded expectations, the Surgical Structural Heart sales underperformed, adding to concerns over revenue growth sustainability. Additional risks, including competitive pressures in the TAVR market and potential delays in the TMTT pipeline, could further hinder the company's ability to maintain growth and adversely affect its stock performance.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.